Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination

Fineline Cube May 17, 2024

Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered...

Company Medical Device

Chunlizhengda’s Handheld Orthopedic Robot Approved by China’s NMPA

Fineline Cube May 17, 2024

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) has received marketing approval from...

Company

Roche Marks 30 Years in China with Commitment to Boost Investments and Local Manufacturing

Fineline Cube May 17, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has reaffirmed its long-term commitment to the Chinese...

Company Deals

Hengrui Pharmaceuticals Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets

Fineline Cube May 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into...

Company Drug

Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer

Fineline Cube May 16, 2024

China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...

Policy / Regulatory

Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment

Fineline Cube May 16, 2024

The US House Committee on Oversight and Accountability has completed the markup process for amendments...

Company Deals

Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support

Fineline Cube May 16, 2024

Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase...

Company Deals

AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation

Fineline Cube May 16, 2024

AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure...

Company Deals

Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO

Fineline Cube May 16, 2024

Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic...

Company Medical Device

Lifetech Scientific’s IBS Stent Demonstrates Non-Inferiority in Phase II Trial

Fineline Cube May 16, 2024

Lifetech Scientific Corporation (HKG: 1302), a biopharmaceutical company based in China, has announced the completion...

Company Drug

Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial

Fineline Cube May 16, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors

Fineline Cube May 16, 2024

China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...

Company Deals Medical Device

GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment

Fineline Cube May 16, 2024

GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent...

Company Deals Medical Device

Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics

Fineline Cube May 16, 2024

Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+...

Company Deals

Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets

Fineline Cube May 16, 2024

Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...

Company Deals Hospital

Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China

Fineline Cube May 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion...

Company Drug

Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch

Fineline Cube May 15, 2024

Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...

Company Deals

Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round

Fineline Cube May 15, 2024

China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...

Company Policy / Regulatory

US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports

Fineline Cube May 15, 2024

The US Office of the Trade Representative (USTR) has announced a series of stringent new...

Company

Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation

Fineline Cube May 15, 2024

Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...

Posts pagination

1 … 352 353 354 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.